MMP-14 and TIMP-2 overexpression protects against hydroquinone-induced oxidant injury in RPE: Implications for extracellular matrix turnover

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 12, 2007, Pages 5662-5670

  Alcazar, Oscar ^a   Cousins, Scott W ^b   Marin Castaño, Maria E ^a,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY EYE CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; COMPLEMENTARY DNA; GELATINASE A; HYDROQUINONE; LAMININ; MATRIX METALLOPROTEINASE 14; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTIOXIDANT; HYDROQUINONE DERIVATIVE; MMP14 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; RNA ISOLATION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; ZYMOGRAPHY; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DRUG EFFECT; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIOXIDANTS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CLONING, MOLECULAR; COLLAGEN TYPE I; COLLAGEN TYPE IV; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC VECTORS; HUMANS; HYDROQUINONES; LAMININ; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; PIGMENT EPITHELIUM OF EYE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION;

EID: 38549098235     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0392     Document Type: Article

References (39)

1. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res. 2001;20:227-253.
2. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd. Age-Related Eye Disease Study Research Group: risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology. 2005;112:533-539.
3. Espinosa-Heidmann DG, Suner IJ, Catanuto P, et al. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47:729-737.
4. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol. 1996;114:1193-1196.
5. Khan JC, Thurlby DA, Shahid H, et al. Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90:75-80.
6. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-1151.
7. DeCaprio AP. The toxicology of hydroquinone: relevance to occupational and environmental exposure. Crit Rev Toxicol. 1999;29:283-330.
8. Monks TJ, Jones DC. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr Drug Metab. 2002;3:425-438.
9. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306.
10. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol. 1999;44:1-29.
11. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med. 1998;76:253-265.
12. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res. 1999;19:1589-1592.
13. Jacot TA, Striker GE, Stetler-Stevenson M, Striker LJ. Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest. 1996;75:791-799.
14. Peten EP, Garcia-Perez A, Terada Y, et al. Age-related changes in alpha 1- and alpha 2-chain type IV collagen mRNAs in adult mouse glomeruli: competitive PCR. Am J Physiol. 1992;263:F951-F957.
15. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331-5338.
16. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997;16:925-929.
17. Marin-Castano ME, Csaky KG, Cousins SW. Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci. 2005;46:3331-3340.
18. Ahir A, Guo L, Hussain AA, Marshall J. Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 2002;43:458-465.
19. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem. 1998;273:871-880.
20. Elliot S, Catanuto P, Stetler-Stevenson W, Cousins SW. Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2. Invest Ophthalmol Vis Sci. 2006;47:1696-1702.
21. Marin-Castano ME, Elliot SJ, Potier M, et al. Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:50-59.
22. Obayashi K, Akamatsu H, Okano Y, Matsunaga K, Masaki H. Exogenous nitric oxide enhances the synthesis of type I collagen and heat shock protein 47 by normal human dermal fibroblasts. J Dermatol Sci. 2006;41:121-126.
23. Chen CP, Yang YC, Su TH, Chen CY, Aplin JD. Hypoxia and transforming growth factor-beta 1 act independently to increase extracellular matrix production by placental fibroblasts. J Clin Endocrinol Metab. 2005;90:1083-1090.
24. Saghizadeh M, Kramerov AA, Tajbakhsh J, et al. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci. 2005;46:3604-3615.
25. Marin-Castano ME, Striker GE, Alcazar O, Catanuto P, Espinosa-Heidmann DG, Cousins SW. Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci. 2006;47:4098-4112.
26. McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol. 2001;119:1455-1462.
27. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001;108:697-704.
28. Belkhiri A, Richards C, Whaley M, McQueen SA, Orr FW. Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest. 1997;77:533-539.
29. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998;58:3743-3750.
30. Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation, role in cell invasion across collagen barrier. J Biol Chem. 2001;276:16248-16256.
31. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
32. Winn LM. Homologous recombination initiated by benzene metabolites: a potential role of oxidative stress. Toxicol Sci. 2003;72:143-149.
33. Kari FW, Bucher J, Eustis SL, Haseman JK, Huff JE. Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice. Food Chem Toxicol. 1992;30:737-747.
34. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1998;1364:222-235.
35. Esmaeli-Azad B, Feinstein SC. A general radiochemical-color method for quantitation of immunoblots. Anal Biochem. 1991;199:275-278.
36. Fernandez E, Kopchick JJ. Quantitative determination of growth hormone by immunoblotting. Anal Biochem. 1990;191:268-271.
37. O'Callaghan JP, Imai H, Miller DB, Minter A. Quantitative immunoblots of proteins resolved from brain homogenates: underestimation of specific protein concentration and of treatment effects. Anal Biochem. 1999;274:18-26.
38. Timpl R. Structure and biological activity of basement membrane proteins. Eur J Biochem. 1989;180:487-502.
39. Langeveld JP, Wieslander J, Timoneda J, et al. Structural heterogeneity of the noncollagenous domain of basement membrane collagen. J Biol Chem. 1988;263:10481-10488.